Our highly experienced lawyers will contact you for a Free Legal Consultation.
If you or someone you love were among those needlessly injured as a result of taking Onglyza, you may be eligible for compensation. The Onglyza lawsuit lawyers at Loncar Lyon Jenkins are investigating cases in all 50 states. Contact Loncar Lyon Jenkins immediately for a free, confidential case evaluation using the form on the side or by calling toll free at 800.285.4878. Onglyza lawsuits are being evaluated on a contingency fee basis, meaning you pay nothing unless a recovery is obtained.
Onglyza (Saxagliptin) is a dipeptidyl peptidase-4 (DDP-4) inhibitor belonging to a new class of medications known as incretin mimetics used for the treatment of type 2 diabetes. It acts to lower the blood sugar of diabetic patients after food consumption when blood sugar levels are highest. It works by forcing the body to produce more insulin. Onglyza was first approved on July 31, 2009 as a medication to supplement diet and exercise to normalize blood sugar levels in patients with type 2 diabetes. DPP-4 inhibitors are a relatively new class of diabetes drugs that have experts concerned about a lack of long-term safety studies. Manufacturers of Onglyza, AstraZeneca and Bristol-Myers Squibb, initiated a study looking to promote the heart benefits of Onglyza in order to quell concerns. Published in October 2013, the manufacturers own study furthered the concerns of experts.
On April 5, 2016 The FDA safety review found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result the FDA mandated warning label changes to Onglyza and Kombiglyze to inform patients of the potential increased risk of heart failure.
December 2, 2015 Update: Kombiglyze to be Included with Onglyza
Kombiglyze contains the same active ingredient, Saxagliptin, as Onglyza but contains metformin and acts as an extended release pill. Kombiglyze was approved in 2010 and is also manufactured by AstraZeneca and Bristol-Myers Squibb. Considering the extreme similarity between Kombiglyze and Onglyza, it carries the same risks of heart failure, pancreatitis, and pancreatic cancer. Loncar Lyon Jenkins is currently evaluating Kombiglyze cases for litigation. If you were injured by this medication or Onglyza, contact our office immediately for a confidential case evaluation.
The Onglyza study sponsored by Astrazeneca and Bristol-Myers Squibb published in The New England Journal of Medicine showed an increased risk of heart failure hospitalization by 27%. In a study of 16,492 patients tracked for a median of 2.1 years, the Onglyza group showed a heart failure hospitalization rate of 3.5% as compared to the placebo group with 2.8%. The increased rate of heart failure hospitalization was significant enough for the FDA to release a February 2014 Onglyza Drug Safety Communication requesting clinical trial data from the manufacturers of Onglyza to investigate a possible association between use of the type 2 diabetes drug and heart failure.
In April 2015 the FDA advisory committee voted (14 out of 15 members) that the FDA add new safety information on the higher risk of cardiovascular hospitalization to the product label. One committee member voted to withdraw the drug from the market entirely. Loncar Lyon Jenkins is continuing to monitor all data regarding Onglyza as the FDA continues to investigate the link between Onglyza and the increased risk of heart failure.
These labeling changes may impact your ability to successfully litigate your case. Do not wait to act. Contact us immediately for a no cost, no obligation review of the facts of your case.
Each year, Loncar Lyon Jenkins represents over 7,000 clients all over Texas and will travel to any city or town within the Lone Star state.
Locations
Each year, Loncar Lyon Jenkins represents over 7,000 clients all over Texas and will travel to any city or town within the Lone Star state.
The mayo clinic provides the following signs and symptoms of heart failure that Onglyza patients should be aware of:
When to see a doctor:
On March 14, 2013 the FDA released a drug safety communication that they were investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. According to a study by Butler, published in the March 2013 issue of Diabetes, one of the claims of DPP-4 drugs is that they increase the number and size of beta cells (cells that are responsible for secreting insulin). In people with Type 2 diabetes, the beta cells shrink or die and lose their ability to produce insulin.
Butler and colleagues found that although the drugs did indeed increase the number of beta cells, the cells become abnormal. They also found small, benign tumors called adenomas that have the potential to become malignant. One of the key findings was that this change only occurred in Type 2 diabetes patients who took DPP-4 or GLP-1 drugs, and not in people with diabetes who took other drugs. As a result of this study, over 100 lawsuits have been filed by patients who developed pancreatitis or pancreatic cancer taking DPP-4 drugs.
If you are a patient taking Onglyza it is important that you see a doctor if you feel that you may be experiencing heart failure, pancreatitis, or pancreatic cancer. Patients should not stop taking Onglyza without the consent of their health care professionals. If you are anyone you know have experienced heart failure, pancreatitis, or pancreatic cancer as a result of taking Onglyza, you may be entitled to a significant claim against the manufacturers. An Onglyza lawsuit lawyer at Loncar Lyon Jenkins can help you build a strong case and pursue compensation to cover the cost of illness-related damages.
Our highly experienced lawyers will contact you for a Free Legal Consultation.
If you are a patient taking Onglyza and are experiencing pancreatic cancer, pancreatitis, or heart failure, contact an Onglya lawsuit lawyer at Loncar Lyon Jenkins to schedule a consultation. Evaluations are free and you pay nothing unless a recovery is obtained. Contact us today to schedule your consultation 800.285.4878.
Locations
Each year, Loncar Lyon Jenkins represents over 7,000 clients all over Texas and will travel to any city or town within the Lone Star state.
Phone: +1 214 747 0422
Fax: 214.382.5838
424 S. Cesar Chavez Blvd. Dallas TX 75201
Dallas Office Information
Houston Office Information
Mon – Fri 8:30 AM – 5:30 PM
Phone: +1 281 290 4500
Fax: 713.649.3725
El Paso Office Information
Lubbock Office Information
McAllen Office Information
Wichita Falls Office Information
Mon – Fri 8:30 AM – 5:30 PM
Phone: +1 940 745 2939
Fax: 940.322.8194
Odessa Office Information
Tyler Office Information
Mon – Fri 8:30 AM – 5:30 PM
Phone: +1 903 300 5766
Fax: 903.509.2983
© Copyright 2024 Loncar Lyon Jenkins
